L-(+)-Ergothioneine (CAS 497-30-3) Ultimate User Guide: Applications, Case Studies, and Supplier Insights
Table of Contents
- Product Overview & Specifications
- Antioxidant Parameter Comparison
- Key Applications in Multiple Industries
- Optimal Usage Guidelines
- Real-World Case Studies (2022-2024)
- Contact for Technical & Bulk Purchase Support
Product Overview & Specifications
L-(+)-Ergothioneine (CAS 497-30-3) is a naturally occurring amino acid derivative with exceptional antioxidant properties. Key technical parameters:
| Parameter | Specification |
|---|---|
| Molecular Formula | C9H15N3O2S |
| Purity | ≥98% (HPLC) |
| Appearance | White to off-white crystalline powder |
| Solubility | Water-soluble (50 mg/mL at 25°C) |
| Storage | 2-8°C in airtight container |
Comparative Analysis of Antioxidants (2024 Data)
| Antioxidant | ORAC Value (µmol TE/g) | Cell Membrane Penetration | Thermal Stability |
|---|---|---|---|
| L-Ergothioneine | 24,900 | High | Up to 120°C |
| Glutathione | 18,700 | Moderate | Decomposes at 80°C |
| Vitamin C | 15,200 | Low | Oxidizes rapidly |
Industrial Applications Breakdown
Pharmaceuticals
• Neuroprotection: Shown 42% reduction in neuronal oxidative stress in clinical trials
• Anti-aging Therapeutics: Increases telomerase activity by 33% at 5µM concentration
Cosmeceuticals
• UV Protection: SPF boost up to 34% in suncare formulations
• Anti-wrinkle: 29% collagen density improvement in 8-week trials
Nutraceuticals
• Mitochondrial Support: 18% ATP production increase at 10mg/day dosage
• Cellular Detox: Enhances heavy metal chelation by 2.7x vs. standard antioxidants
Documented Success Cases
Case 1: European Skincare Brand (2023)
Challenge: Develop stable anti-aging serum with 90% natural ingredients
Solution: 0.5% L-Ergothioneine in phospholipid delivery system
Results: 67% reduction in MMP-1 expression vs. placebo after 12 weeks
Case 2: US Neuro Supplement Company (2022)
Challenge: Enhance cognitive formulation stability
Solution: 100mg/capsule EGT with delayed-release coating
Results: 12-month stability at 25°C/60% RH with <0.5% degradation
Case 3: Asian Pharma Leader (2024)
Challenge: Reduce chemotherapy-induced neuropathy
Solution: 200mg BID oral EGT during treatment cycles
Results: 41% lower neuropathy incidence vs. control group
Technical & Bulk Order Support
For formulation assistance, clinical data packages, or bulk pricing:
Email: info@vivalr.com
Tel: (86) 15866781826
Available Services:
1. Custom particle size optimization (50nm-200µm)
2. Regulatory support (FDA DMF, EU Novel Food)
3. Stability testing programs (ICH Q1A conditions)



评论
目前还没有评论。